Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation
Nitin Sahi, Syed Muhammad Ali Abidi, Omar Salim, Roby Abraham, Seema Kalra, Adnan Al-Araji
Topics & Concepts
MedicineDosingMultiple sclerosisOcrelizumabExpanded Disability Status ScalePopulationInternal medicineImmunologyLymphomaRituximabEnvironmental healthSARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis